Exact Sciences Corp is a molecular diagnostics company specializing in the development of non-invasive tests for various types of cancers. Its flagship product, Cologuard, is a US FDA-approved stool-based DNA screening test for colorectal cancer. The company also offers Oncotype DX gene expression tests for prostate, breast, and colon cancers, as well as other precision oncological tests.

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

COM:EXACTSCIENCES

Exact Sciences Corp

Last Close

71.13

05/11 21:00

Market Cap

8.36B

Beta: -

Volume Today

3.89M

Avg: -

market

industry

website

crunchbase

ipo date

peer of

investor of

competitor of

Metrics